DOMISOL: This study is recruiting people with advanced solid cancers to evaluate a new immunotherapy drug (called DT-7012) by itself and in combination with other immunotherapy treatmentsA Phase 1/2, Multicentre, Open-label Clinical Trial of DT-7012 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Selected Advanced Solid Tumors (DOMISOL, DOmain_therapeutics Monoclonal antIbody for SOLid Tumors)

Trial purpose

Cancer treatment

Tumor type

Multi-Cancer

Age

18+

Trial acronym

DOMISOL

Summary

This study is recruiting people with certain recurrent, advanced or metastatic solid cancers to assess how safe and effective a new immunotherapy called DT-7012 is when given by itself (monotherapy) and in combination with an immune checkpoint inhibitor. DT-7012 is a monoclonal antibody, that targets and binds to CCR8 receptors to improve the anti-tumour immune response.

The study has two parts.

Part 1 has two arms: dose escalation of DT-7012 given as monotherapy, and dose escalation of DT-7012 given in combination with an immune checkpoint inhibitor.

Part 2 will further evaluate DT-7012 as monotherapy and/or in combination with an immune checkpoint inhibitor in expansion cohorts of 2-3 specific cancer types.

All treatments will be given as intravenous infusions.

Eligible tumour types include: non-small cell lung cancer, triple neative breast cancer, HR+ breast cancer, ovarian cancer, cervicacl squamous cell carcinoma, head and neck squamous cell carcinoma, renal cell carcinoma, stomach cancer, oesophageal cancer, liver cancer, pancreatic cancer or bowel cancer (colorecal).

Conditions

This trial is treating people with recurrent, locally advanced or metastatic solid cancers that have progressed on at least one prior line of treatment and have no established curative option